Dassault Systèmes to Acquire ArisGlobal for Up to $2 Billion
Dassault Systèmes, the French software giant behind industrial "virtual twins," is spending up to $2 billion to buy the American drug-safety firm ArisGlobal. This strategic move into artificial intelligence (AI) comes as the company navigates a nervous period, with shares down, a recent change in leadership, and concerns about AI’s potential disruption of its core business.
A Big Bet on AI in Life Sciences
July 24, 2026 – 2:15 pm
(Image by: Dassault Systèmes)
The French firm has agreed to acquire ArisGlobal, a maker of drug-safety and regulatory software, for approximately $1.8 billion in cash, plus up to $200 million more contingent on future AI revenue. Nordic Capital, a Swedish private-equity group that has owned ArisGlobal since 2019, will sell the company. The entire acquisition is funded by Dassault’s own cash reserves.
What Dassault Is Acquiring
ArisGlobal, while not a household name, plays a crucial role in the pharmaceutical industry. Founded in 1989 and based in Waltham, Massachusetts, ArisGlobal serves more than 200 customers, including half of the world’s top 50 drugmakers, various biotechs, and government health regulators. Its software processes over 12 million patient safety reports annually. With projected revenue of about $175 million in 2026, ArisGlobal is expected to grow its market for compliance software to $7.5 billion by 2030.
AI Integration and Market Trends
The attraction for Dassault lies in ArisGlobal’s AI capabilities. ArisGlobal’s NavaX system leverages generative AI to streamline drug-safety monitoring and regulatory filing tasks, which are typically manual and strictly regulated. The company claims this technology reduces these tasks by more than 30%.
Dassault is not alone in its pursuit; legacy software giants such as SAP and Adobe have also acquired their way into AI rather than developing it in-house.
Virtual Twins and Real-World Data
Dassault’s specialty is creating "virtual twins," detailed digital replicas of real machines, factories, and even humans. Chief Executive Pascal Daloz aims to combine these virtual models with ArisGlobal’s real-world patient data to create the industry’s first platform unifying real-world evidence with virtual evidence.
"Life Sciences is entering a new era of innovation, driven by AI and the shift to precision medicine," said Daloz.
ArisGlobal CEO Aman Wasan expressed a similar sentiment: "The future of Life Sciences will not be built on better software. It will be built on connected intelligence."
A Deal Born of Pressure
This acquisition comes amid significant pressure for Dassault, which has struggled against the backdrop of AI’s potential to upend its core business. The company ousted its chairman in February as stock prices declined, marking a turning point. This is Dassault’s first major deal since then.